Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a new, recently approved therapy for diabetes mellitus type 2 (Wanner et al., 2016), also with beneficial effects in type 1 diabetes (Henry et al., 2015). The gene discussed is SLC5A2; the disease is type 1 diabetes mellitus.